Abstract
Suprachoroidal hemorrhages were created in 15 albino rabbit eyes by injecting 0.1 cc of autologous blood into the suprachoroidal space. One day later, 10 of these eyes were treated with intravenous tissue plasminogen activator (TPA). Doses of 1 mg per kg were given to each rabbit over 2 to 3 hours by intravenous infusion. Five eyes served as control. The rate of clearance of hemorrhage was compared in the two groups. Average day of clearance was 14 days for the treated group, and 20.2 for the untreated control group. In this study, TPA given intravenously appears to accelerate the clearance of suprachoroidal hemorrhage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ariano ML, Ball SF. Delayed non-expulsive suprachoroidal hemorrhage after trabecularectomy. Ophthalmic Surg 1987; 18: 661–6.
Bergman SR, Ludbrook PA, Sobel BE. Coronary thrombolysis with tissue-type Plasminogen activator. Cardiol Clinics 1987; 5: 101–11.
Givens K, Shields MB. Suprachoroidal hemorrhage after glaucoma filtering surgery. Am J Ophthalmol 1987; 103: 689–94.
Gressel MG, Parrish II RK, Heuer DK. Delayed nonexpulsive suprachoroidal hemorrhage. Arch Ophthalmol 1984; 102: 1757–60.
Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol 1987; 104: 619–23.
Lambrou FH, Snyder RW, Williams GA. Use of tissue plasminogen activator in experimental hyphema. Arch Ophthalmol 1987; 105: 995–7.
Oncel M, Peyman GA, Khoobehi B. Tissue plasminogen activator in the treatment of experimental retinal occlusion. Retina 1989; 9: 1–7.
Rao AK, Pratt C, Berke A, Jaffe A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11.
Robinson AK, Collen D. Activation of the fibrinolytic system. Cardiol Clinics 1987; 5: 13–9.
Ruderman JM, Harbin TS, Campbell DG. Postoperative suprachoroidal hemorrhage following filtration procedures. Arch Ophthalmol 1986; 104: 201–5.
Simmons ML, Betrin A, Col J, Von Essen E, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. The Lancet Jan 30, 1988; pp197–203.
Snyder RW, Lambrou FH, Williams GA. Intraocular fibrinalysis with recombinant human tissue plasminogen activator. Arch Ophthalmol 1987; 105: 1277–80.
Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator: Emerging strategies. J Am Coll Cardiol 1986; 8: 1220–5.
Verstraete M. New thrombolytic drugs in acute myocardial infarction. Theoretical and practical considerations. Circulations 76: (Suppl II) 1987; II 31-II 38.
Williams DO, Borer J, Braunwald E, Chesebro JH. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction trial. Circulation 1986; 73: 338–46.
Author information
Authors and Affiliations
Additional information
Supported in part by Public Health Service Grant EYO2377, from the National Eye Institute, National Institutes of Health, Bethesda, Md.
Rights and permissions
About this article
Cite this article
Liu, J.C., Peyman, G.A. & Oncel, M. Treatment of experimental suprachoroidal hemorrhage with intravenous tissue plasminogen activator. Int Ophthalmol 14, 267–270 (1990). https://doi.org/10.1007/BF00159862
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00159862